Overview

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2024-07-10

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of chidamide in combination with camrelizumab and carboplatin or capecitabine in the second and third line treatment of relapsed/metastatic triple-negative breast cancer

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Capecitabine
Carboplatin